CombiPatch

CombiPatch®

Estalis® Gynecology A dermal patch containing estradiol/norethindrone acetate used to manage the vasomotor Sx of menopause; vulvar and vaginal atrophy; hypoestrogenism due to hypogonadism, castration, or primary ovarian failure
References in periodicals archive ?
Estraderm and CombiPatch (Novartis) for menopausal symptoms
Novogyne manufactures the hormone therapy patches, Vivelle-Dot, Vivelle, and CombiPatch.
Novogyne manufactures the hormone therapy patches Vivelle-Dot, Vivelle, and CombiPatch.
Archer DF, Furst K, Tipping, et al for the Combipatch Study Group.
015 mg/day of levonorgestrel) than CombiPatch, the first estrogen and progestin patch on the U.
015 rag/day of levonorgestrel) than CombiPatch, the first estrogen and progestin patch on the U.
Cost/day is based on the average wholesale price for combiPatch in the 2002 Red Book.
For menopausal women with an intact uterus, CombiPatch (estradiol/norethindrone acetate) transdermal system relieves such moderate-to-severe vasomotor symptoms as hot flashes, night sweats and vaginal dryness, according to Gary Shearman, the company's senior vice president of development and deputy head of research and development.
Before the debut of CombiPatch women who would benefit from both estrogen and progestin were prescribed either oral estrogen and progestin or an estrogen transdermal patch used In conjunction with oral progestin.
Comment: In studies of postmenopausal women, those treated with CombiPatch had a significant reduction in the number and intensity of daily hot flashes, compared with those on placebo.
3 million, reflecting lower sales of CombiPatch due to the continuing effects of the Women's Health Initiative ("WHI") study and the entry of a new combination patch competitor, as well as the impact of trade customer purchasing patterns on sales of Vivelle(R) family products.